

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
05 FEB 14 PM 3:36

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name PodestaMattoon			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1001 G Street, NW Suite 900 East City Washington State/Zip (or Country) DC 20001			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Jeff Cordeau	Telephone 202-879-9366	E-mail (optional) jcordeau@podestamattoon.com	5. Senate ID # 31680-101
7. Client Name <input type="checkbox"/> Self Biotechnology Industry Organization			6. House ID #

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-D

9. Check if this filing amends a previously filed version of this report ☐


10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$40,000.00</u> <small>Income (nearest \$20,000)</small> Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <small>Expenses (nearest \$20,000)</small> 14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of methods. <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6011 of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162 of the Internal Revenue Code

Jeff Cordeau

Signature  Date _____

Printed Name and Title **Sharon Cohen - Principal** I

Registrant Name: PodestaMattoonClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues
Patent Fees in the Omnibus Appropriations Bill

17. House(s) of Congress and Federal agencies contacted


☐ Check if None


Department of Health & Human Services
Department of Homeland Security
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Cohen, Sharon	
Hembree, Shannon	
Morra, Elizabeth	
Siciliano, Jen	Dir. of Communications, Senate Appropriations C

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None


Signature  Date 11/11/2011

Printed Name and Title Sharon Cohen - Principal

Registrant Name: PodestaMattoonClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

S.15 , Biodefense Improvement and Treatment for America Act,
S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguard,
S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004 ,
S.2384, To amend the Small Business Act to permit business concerns that are owned by venture capital op
companies or pension plans to participate in the Small Business Innovation Research Program.
,
S.2493, Safe IMPORT Act of 2004 ,
FDA drug approval issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None


Department of Health & Human Services
Department of Homeland Security
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Cohen, Sharon	
Hembree, Shannon	
Morra, Elizabeth	
Siciliano, Jen	Dir. of Communications, Senate Appropriations C

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None


Signature  Date 11/11/11

Printed Name and Title Sharon Cohen - Principal

Registrant Name: PodestaMattoonClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

S.15 , Biodefense Improvement and Treatment for America Act,
S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguards
S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004 ,
S.2384, To amend the Small Business Act to permit business concerns that are owned by venture capital op
companies or pension plans to participate in the Small Business Innovation Research Program.
S.2493, Safe IMPORT Act of 2004 ,
FDA drug approval issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None


Department of Health & Human Services
Department of Homeland Security
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Cohen, Sharon	
Hembree, Shannon	
Morra, Elizabeth	
Siciliano, Jen	Dir. of Communications, Senate Appropriations C

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None


Signature  Date 11/1/2020

Printed Name and Title Sharon Cohen - Principal I

Registrant Name: PodestaMattoonClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

S.15 , Biodefense Improvement and Treatment for America Act,
S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguard,
S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004 ,
S.2384, To amend the Small Business Act to permit business concerns that are owned by venture capital op
companies or pension plans to participate in the Small Business Innovation Research Program.
S.2493, Safe IMPORT Act of 2004 ,
FDA drug approval issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None


Department of Health & Human Services
Department of Homeland Security
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Cohen, Sharon	
Hembree, Shannon	
Morra, Elizabeth	
Siciliano, Jen	Dir. of Communications, Senate Appropriations C

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None


Signature  Date

Printed Name and Title **Sharon Cohen - Principal** I